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Study objectives -  Sociodemographic differentials in cancer survival have occasionally been studied by using a relative-survival 
approach, where all-cause mortality among persons with a cancer diagnosis is compared with that among similar persons without 
such a diagnosis (’normal’ mortality). One should ideally take into account that this ’normal’ mortality not only depends on age, 
sex and period, but also various other sociodemographic variables. However, this has very rarely been done. A method that 
allows such variations to be considered is presented here, as an alternative to an existing technique, and is compared with a 
relative-survival model where these variations are disregarded and two other methods that have often been used.  
Design, setting and participants – The focus is on how education and marital status affect the survival from twelve common 
cancer types among men and women aged 40-80. Four different types of hazard models are estimated, and differences between 
effects are compared. The data are from registers and censuses and cover the entire Norwegian population for the years 1960-
1991.  There are more than 100 000 deaths to cancer patients in this material.  
Main results and conclusions - A model for registered cancer mortality among cancer patients gives results that for most, but not 
all, sites are very similar to those from a relative-survival approach where educational or marital variations in ’normal’ mortality 
are taken into account. A relative-survival approach without consideration of these sociodemographic variations in ’normal’ 
mortality gives more different results, the most extreme example being the doubling of  the marital differentials in survival from 
prostate cancer. When neither sufficient data on cause of death nor on variations in ’normal’ mortality are available, one may 
well choose the simplest method, which is to model all-cause mortality among cancer patients. There is little reason to bother 
with the estimation of a relative-survival model that does not allow sociodemographic variations in ’normal’ mortality beyond 
those related to age, sex and period. Fortunately, both these less data demanding models perform well for the most aggressive 
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•  The model (1a) proposed here allows a broad range of sociodemographic variations in ’normal’ 
mortality to be taken into account, and is a convenient alternative to an existing technique. 
•  If sufficient data on sociodemographic variations in ’normal’ population are not available, the best 
solution is to model registered cancer mortality among cancer patients (model 2b). 
•  If  cause-specific mortality data are not available either, there is little need to bother with the 
estimation of a relative-survival model (1b). One may just as well estimate all-cause mortality 
among cancer patients (model 2a). 




Assessment of prognosis is a key issue in cancer epidemiology. It is important not only to check the impact 
that different kinds of treatment have, but also to map the overall trends in survival, and to find out whether 
some groups of the population fare worse than others when faced with a malignant disease. For example, a 
reduction of the social differentials in mortality is widely accepted as a major challenge, and appropriate 
interventions will require an accurate description of its sources, i.e. the differentials in the incidence of and 
survival from various important diseases, such as the neoplasms. It would also be important, but much more 
difficult, to identify the mechanisms behind these differentials. Generally, cancer survival is considered to 
be determined by three types of factors: treatment, so-called host factors, and stage at the time of diagnosis 
(see e.g. discussion in [1,2]). While the latter is taken into account in some studies (including the present), 
the relative importance of the two other causal channels is very hard to establish. This is regrettable, 
because population differences in treatment, with consequences for survival, would trigger another health 
policy response than survival gradients stemming from, for example, the patients’ general health at the time 
of diagnosis.   
  A majority of the quite few studies of sociodemographic determinants of cancer survival suggest that 
being married or having a higher education or income is beneficial.[1,2] However, some studies point in the 
opposite direction, and there is no agreement on whether there are sharper survival differentials for some 
cancer sites than for others. A good assessment of such differentials across sites could be an important lead 
in the search for explanations. For example, if the social gradients to a large extent were due to treatment 
differentials, one would expect them to be more pronounced for cancers for which an efficient treatment is 
reckoned to exist, than for those thought to be relatively unresponsive to treatment.   
  The mixed results in previous studies are partly due to the different data that are used, and their often 
small size. Besides, different countries, with more or less well-developed public health care systems, have 
been analysed, and different methods have been employed. Better knowledge about the qualities of the               
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various methods will be of importance when assigning weights to previous studies in a review, and for 
choosing a good design in future research. In addition, it would, of course, be valuable to try to develop 
better or more convenient alternatives to existing techniques.  
Two main approaches have been used in studies of how marital status, education and other 
sociodemographic factors affect cancer survival. The first is simply to estimate mortality differentials 
among people who have been diagnosed with the types of cancer under investigation, with controls for age 
and sex and perhaps some other potentially confounding factors (see e.g. Krongrad et al [3]). This is 
referred to in the survival literature as observed survival. During the follow-up period, many of these 
patients will die from causes that are obviously unrelated to their malignancies. In an attempt to exclude 
these deaths, it is a common strategy to count only the deaths recorded as due to cancer and censor the 
observations at the time of other deaths (see e.g. Neale [4]). This is the corrected or cause-specific survival. 
 The other approach is based on a comparison of all-cause mortality among cancer patients with that 
among other persons without such a diagnosis, denoted below as ’normal’ mortality. One advantage of this 
so-called relative-survival approach is that data on cause of death are unnecessary. Besides, such a measure 
of the aggressiveness of the disease will include the excess deaths that are caused by the malignancy, but 
which would not (and perhaps should not) be recorded as cancer deaths. Published national mortality rates, 
grouped by age, sex and period, have usually been taken as the ’normal’ mortality in relative-survival 
analyses. In many studies, such measures of excess mortality have been estimated for separate groups of 
patients (see e.g. Gilliland et al. [5]), while other studies have been based on multiple regression (see e.g. 
Schrijvers et al. [6]). Special regression techniques have been developed for relative survival analysis, for 
example by Hakulinen and Tenkanen [7] and Esteve et al. [8]. The former will be referred to below as the 
(simple) HT-version of the relative survial approach.    
Ideally, when the goal is to assess the impact of, for example, social factors on cancer survival, also 
the corresponding variations in ‘normal’ mortality should be taken into account. Such an extension was               
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made in a study by Dickman et al. from 1998 [9], where social-status specific mortality rates for Finland 
were included as ’normal’ mortality within the Hakulinen-Tenkanen approach. This will be called the 
extended HT-version of the relative survival approach. For some cancer sites, the results were found to be 
markedly different from those obtained with a ’normal’ mortality depending only on age, sex and period. In 
fact, the latter method was also found to be inferior to the cause-specific survival approach. 
Since 1996, also another model that allows a broad range of sociodemographic variation in ’normal’ 
mortality has been used in cancer survival studies.[1,2,10,11] This model is estimated from a combined 
sample of cancer patients and people without such a diagnosis, and is therefore referred to below as a CS-
version. To conform to the other names just given, the model can be called an extended CS-version of the 
relative survival approach when sociodemographic factors other than age, sex and period are included in 
the term for ’normal’ mortality, and otherwise substitute the word ’extended’ with ’simple’.  
One objective of this paper is to present this alternative approach. It is not likely to produce other 
results than the corresponding HT-version, but it may be more convenient in some situations. The other 
objective is to compare it with the three other models mentioned above, i.e. observed survival, cause-
specific survival, and relative survival without control for ’normal’ mortality variations except those related 
to age, sex and period (the latter in its CS-version). This adds to the Finnish work referred to above. Above 
all, the observed survival method, which is particularly attractive because of its modest data requirements, 
was not included for comparison in the Finnish study. Besides, it is valuable to replicate that comparison, 
using other data, another technical set-up (CS rather than HT), other sociodemographic variables, and 
partly other cancer sites, to see if the conclusions are confirmed. The focus is on education and marital 
status, rather than social status, as in the Finnish study. 
A discussion of possible behavioural mechanisms behind the estimated effects of these variables (as 
well as occupation and income) can be found elsewhere.[1,2] 
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To set the stage for the presentation of  the novel and most complex model, the basic ideas behind the 
relative survival approach are first reviewed. The three alternative models, which are simpler and to some 
extent special cases of each other, should then need little elaboration. The formal specification of all 
models is followed by a brief description of data and an account of some technical details. For pedagogical 
purposes, the differences between the models are illustrated in a graph. 
  A piecewise constant mortality rate is assumed in all models. With such specification, one can 
generally get a better fit to the duration pattern than with the less flexible parametric models. Besides, 
models with piecewise constant rates and categorical covariates are convenient to estimate, and are, in fact, 
indistinguishable from Poisson regression (of number of deaths with exposure time as ’offset’, i.e 
conditional on exposure time) [12]. This means that one can make use of the Poisson regression module in 
Epicure, which has the special advantage that it allows the partly additive structure needed for the relative 
survival approach.  
 
The rationale for the relative-survival approach 
 
The idea behind the relative-survival approach is illustrated in Figure 1, which is drawn for a given age, 
sex and period. The bold line is mortality for persons without a cancer diagnosis (µn). It is depicted, for 
simplicity, as declining linearly with educational level, but that is of no importance for the argument that 





(Figure 1 about here) 
 
Among those who have received a cancer diagnosis, death is, of course, very often registered as the 
result of cancer. This ‘registered cancer mortality’ is denoted here as µcc, while the cancer patients’ all-
cause mortality is µa. In addition, it is likely that persons with a cancer diagnosis may suffer an extra high 
non-cancer mortality as a result of their disease, i.e. that  their mortality from other registered causes (µm) is 
higher than that among  other persons (µn).  To give just one example, the emotional stress from cancer 
may increase the chance of being involved in a motor vehicle accident, which may then (correctly) be 
registered as the cause of death.  
Because of this blurredness of the cause of death, and because cause-specific mortality data are not 
always available, ‘relative survival’ was suggested several decades ago as a fruitful measure of the 
aggressiveness of the disease. It is defined as the ratio of (all-cause) survival for cancer patients within, 
say, a 5-year interval to that among persons without such a diagnosis, and corresponds to the sum µc of µcc 
and µcn.  (When mortality of a cancer patient is µ = µa = µn + µc and that of another person is µ = µn , relative 
survival can be found by exponentiating the negative integral of µc over the relevant duration interval. 
Mathematically, 5-year relative survival is R5 = exp(- ∫ µa dw)/ exp(- ∫ µn dw) = exp(- ∫ µc dw), where the 
integration is over duration w=0 to w=5 years.)  
 
The novel approach: An extended CS-version of the relative survival approach (Model 1a) 
 
The extended CS-version is specified as  
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   µ = e
 b x + y e 
c x e 
d z 
 
where µ is all-cause mortality and x is a  vector of categorical sociodemographic variables (co-variates), 
such as age, period, educational level and marital status. b and c are effect vectors, and y is a cancer-
diagnosis indicator that takes the value 1 from the time of diagnosis (if any) of the cancer under 
investigation, and otherwise is 0. The co-variate vector z includes various characteristics of the disease, and 
d is the corresponding effect vector.  
For a person without the cancer in focus (i.e. y=0), and with sociodemographic characteristics x, 
mortality is e 
b x. This is, of course, the multiplicative structure we usually see in hazard models, and it 
means that mortality is a product of various positive factors. This first additive term, e 
b x , is referred to in 
this study as ‘normal’ mortality. It is close to, but not exactly equal to, the national mortality level, as 
people with this particular cancer, which is a quite small group, are left out. The second term, e 
c x e 
d z , is 
always positive and is the excess mortality of otherwise similar persons who have been diagnosed with this 
particular type of cancer.  
 
The three simpler models used in previous studies 
 
Model 1b: The simple CS-version of the relative survival approach  
 
The inclusion of only age, sex and period in the first term, and not education or marital status, can be 
symbolized by a different covariate  x- in the equation, which thus looks like:  
 
  µ = e
 b’ x- + y e 
c’ x e 




This means that ’normal’ mortality (given age, sex and period) is assumed to be a constant line µn- 
rather than a varying µn.  
  This model is essentially the same as the simple HT-version of the relative survival approach, except 
that ’normal’ mortality is modelled, rather than taken as constants.  
 
Model 2a: Observed survival 
 
The simplest approach is to model all-cause mortality for a sample of cancer patients exclusively. This 
model can be written as  
 
   µa= e
 g x  e 
h z 
 
Model 2b: Cause-specific survival 
 
Alternatively, one may estimate cancer patients’ risk of dying from cancer, according to the ’main cause’ 
of death recorded on the death certificates. The model thus becomes   
 




In the Norwegian data, a large majority of those who die within 5 years of diagnosis are reported as 
dying from the malignant disease. The proportion is 70-95%, depending on the cancer site, with 90% as an 







The analysis is based on individual sociodemographic biographies for all men and women with a 
Norwegian identification number (i.e., all those  who have lived in Norway for some time after 1960). 
These life histories have been extracted from the Norwegian Population Register, the Cause of Mortality 
Register and the Population Censuses of 1960, 1970 and 1980, and include information about date and 
cause of death and all changes in residence, as well as marital status, education, income and occupation at 
the time of the censuses. They  have been linked with data from the Norwegian Cancer Registry, which 
from 1953 has received information on all cancer cases in the population (site, basis for the diagnosis, 
histologic grade and type, and the stage of the disease at the time of diagnosis). These linked data have 
been used in several previous studies.[1,2,10,11,13] 
Twelve common cancer sites are considered in the analysis. At ages 40-80 during the observation 
period 1960-1991, there were more than 150 000 deaths among men or women diagnosed with cancer less 




In all these models, the men and women are followed from age 50 (or 40 in models for leukemia, malignant 
melanoma, and cancer in the breast or female genitals, which tend to occur at a lower age) or, if born 
before 1910 (or 1920), from 1960. It is censored at age 80 (because of potentially inadequate case 
ascertainment at higher ages), at the time or emigration, or by the end of 1991, which was the end of the               
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follow-up period. Moreover, individuals are excluded from the analysis (i.e., contribute neither exposure 
nor deaths) during periods when they lived in another country. In addition, those who did not participate in 
one of the censuses are excluded during the 10 years after this census. These two restrictions have very 
little influence on total exposure time. The very few persons with a cancer diagnosed at autopsy are treated 
as having never received a cancer diagnosis. (Estimated survival gradients might be slightly affected, 
because of possible sociodemographic differentials in the diagnostic intensity or autopsy frequency, but 
this should be of no concern when the focus is on differences between models). 
  Some cancer types may cause death already after a few months, while others may be relatively 
harmless for many years, perhaps followed by recurrences. In this study, the observations are censored 5 
years after diagnosis, if any. This interval is commonly used in cancer survival analysis. The model thus 
provides information on how the various sociodemographic variables influence excess mortality ’on the 
whole’ over the 5 years after diagnosis. (A more detailed picture could have been established by including 
interactions with duration since diagnosis, or by estimating additional models for other interval lengths.)  
  Mortality is assumed to be constant within 5-year age groups, which was  experimentally found to be 
a sufficient control for age.  
There is no distinction between persons who had previously been diagnosed with another type of 
cancer and those for whom the cancer in focus was the first one.  
All co-variates are categorical. They are also time-varying: a level for the co-variate is defined for 
each month  during the follow-up period, and refers to the situation at that time (age, period) or that in the 
last previous census (education and marital status). 
The z-vector includes sub-site, stage and histologic type and/or grade, whenever relevant. Stage is 
defined as localized, regional spread, distant spread, or unknown. The categorization of histology and sub-
site differs across cancer sites and is explained in notes to Table 2. The intention behind the categorization               
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is to distinguish at least between quite large histologic groups or sub-sites associated with markedly 
different survival rates.  
In addition, a few models that are not site-specific are estimated. A site variable is then included in z, 
and  (for the models 1a and 1b) y takes the value 1 from the time of diagnosis of any of the 12 cancers. 
Only the first cancer diagnosis is considered in this set-up.  
The models are estimated in the Amfit Poisson-regression module in the Epicure software. [14] A 
self-made computer program (written in Pascal), operating on the individual-level register and census data, 
was used to compute the tables of deaths and exposures that were fed into Amfit. For each individual and 
each month of follow-up, a contribution of one month was added in the appropriate cell of the exposure 
table (defined according to the level of each co-variate at that time). One death was added to the table of 





Education effects estimated from the model that allows educational variations in ’normal’ mortality 
 
For pedagogical purposes, all estimates from model 1a, including those for variations in ‘normal’ mortality, 
are shown for one cancer site. Colorectal cancer has been chosen (Table 1). Men in the arbitrarily chosen 
reference category (i.e. aged 65-69, observed 1960-69, compulsory education)  have a ’normal’ mortality 
of 0.0025 deaths per person month.  Otherwise similar men who have a post-secondary education at a low 
level have a ‘normal’ mortality that is 25 % lower, while it is 36 % lower for the few who have reached a 




Turning now to the second term, it is found that men in the reference category who have a localized, 
well differentiated adenocarcinoma in caecum or ascendence (which is the reference category for the 
disease variable) experience 0.0051 deaths per person month more than otherwise similar men without this 
disease. For those who have an education at a Master’s level, but are otherwise similar, the corresponding 
excess mortality is 17 % lower than this. The excess mortality declines monotonically with education. 
 
(Table 1 about here) 
 
The estimated effects of educational level on excess mortality from colorectal cancer in men are 
shown also in Table 2, along with corresponding estimates from other cancer sites and for women. The 
figures at the bottom of the table are for all the 12 cancer sites pooled.  
 
Education effects estimated from other models 
 
In Table 3, the estimates shown in Table 2 are compared with those from the three other models. For 
simplicity, men or women with only compulsory education, which are the reference group, are excluded 
from this table.  (To facilitate the reading of the table, differences of 0.03-0.05 are shown in bold types and 
those larger than 0.05 in underlined bold types.)  
When ‘normal’ mortality is assumed to be independent of education (model 1b), the excess mortality 
of those with secondary or higher education compared to those with only a compulsory education becomes 
smaller. In other words, the effects of education on survival become sharper. 
The differences are minor for some malignancies, such as lung cancer, pancreas cancer and stomach               
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cancer, but are quite large for prostate cancer, bladder cancer and malignant melanoma. According to 
model 1b, men with an education at the Master’s level would have an excess mortality from prostate cancer 
that is 44 % lower than that among men with only compulsory education. However, when it is taken into 
account that they would have had a much lower mortality also in the absence of the disease (model 1a), this 
advantage is reduced to 34 %. The corresponding figures for men with 1-4 years of secondary education 
are 11 % and 4 %. 
Because the control for educational differentials in ‘normal’ mortality has little impact for most of the 
cancer sites, the differences between models 1a and 1b are rather small when all sites are pooled. They 
range from 0.02 to 0.05.  
 
(Tables 2 and 3 about here) 
 
While the exclusion of education from the first term of the model reduces the estimated excess 
mortality relative to the reference category (i.e. gives an exaggerated impression of the importance of 
educational level for survival), there is a further change in the opposite direction when the term is entirely 
removed (model 2a).  With only quite few exceptions, the estimates are closer to 1 than those obtained 
from model 1b, and thus also nearer those from model 1a. 
If only the deaths reported as due to the cancers in focus are counted (model 2b), the effects of 
education are, on the whole, slightly weaker. When all cancer sites are pooled, the differences between 
model 2a and model 2b are 0.01-0.03.  
 
Marital status effects 
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Similar patterns appear when marital status is considered instead of education. The effects of marital status 
on excess mortality from different types of cancer, according to the most complex model (1a), are shown in 
Table 4.  
The differences in  ‘normal’ mortality are even larger for marital status than for education. Never 
married men have a 30 % higher ‘normal’ mortality than the married, while that of widowers is 25% higher 
and that of the divorced 79 % higher (not shown). The corresponding figures for women are lower.  
Divorced men are found to have an excess mortality from prostate cancer that is 45 % higher than 
that of married men, according to model 1b, but when their much higher mortality in the absence of the 
disease is taken into account (model 1a), this difference is reduced to 23 % (Table 5). Similarly, the 
relatively high excess mortality for widowers completely disappears, and that for never-married is almost 
halved, from 24 % to 14 %. 
Quite large differences between models are found also for colorectal cancer, bladder cancer, and 
malignant melanoma. The differences between models 1b and 2a are as explained above for models 
including educational level: By and large, estimates from model 2a are nearer 1 and nearer those from 
model 1a.  
If registered cancer mortality is modelled instead (model 2b), the effects are, on the whole, slightly 
weaker than those from model 2a. When all cancer sites are pooled, the differences between model 2a and 
model 2b for divorcees are 0.03-0.04. The differences are smaller for the never-married and widowed. 
 
(Tables 4 and 5 about here) 
 
DISCUSSION 
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A view to the Hakulinen-Tenkanen version 
 
In the HT-version of the relative survival approach, ’normal’ mortality (or , rather, survival) rates are defined 
for relevant sub-groups, for example all possible combinations of age, sex, and period, and considered as 
constants. A ratio between patient survival and ’normal’ (often denoted as ’expected’) survival is calculated for 
each co-variate combination (cell). Using a log-log transformation of this ratio, which yields a linear structure 
of sociodemographic (and other) effects, the estimation is easily carried out in  the GLIM software. 
  In the extended version of this [9], social-status-specific ’normal’ mortality rates were first calculated 
from individual data (but, as explained in the paper, they could also have been taken from published life tables 
adjusted by social-status correction factors derived from other sources). However, if such individual data exist, 
and can be linked with data on cancer diagnosis, also model 1a presented here can be estimated. Model 1a 
should in some respects be slightly more satisfying, without necessarily giving perceptibly different results.  
First, ’normal’ mortality is not treated as a constant. When data for a large national population are used 
to establish ’normal’ mortality, it is, of course, acceptable to use only point estimates for each cell and disregard 
information on variance. This is less satisfying when one has access only to a smaller sample (perhaps 
supposed to be representative of the national population). When variances in ’normal’ mortality are no longer 
negligible compared to the variances in patient mortality, disregarding the variation between cells in these 
variances (by essentially setting them all to 0) will, in principle, affect even point estimates of effects.  
Second, ’normal’ mortality in model 1a does not include the mortality among the cancer patients in 
focus, which may be a non-negligible contribution for some very common and aggressive cancer types.  
Third, the log-log transformation in the HT version requires that cells with no surviving cancer patients, 
which may be found especially when the patient sample is small, must be excluded from the analysis. This 
could have an effect on estimates.                
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Fourth, it is practically convenient to have a one-step approach rather than an approach that requires 
first the estimation of ’normal’ mortality rates, which are then used in a second step to estimate gradients in 
relative survival. On the other hand, such an argument may count little compared to software preferences. 
Researchers who are used to working with GLIM may prefer the HT-version despite its two-step nature, 
whereas those familiar with Epicure may prefer the CT-version.  
Also Oksanen (in an unpublished doctoral dissertation from 1998) has modelled ’normal’ mortality, 
rather than treating it as a constant.[15] Only age and period were included in this first additive term but, unless 
computational problems are met, it should be possible to include also other variables. The data source for 
’normal’ mortality was national aggregate tables on deaths and size of sub-populations in different cells, from 
which the corresponding numbers for cancer patients were substracted. After this data manipulation, estimation 
was carried out in GLIM.   
 
 
Comparison with model 1b 
 
The differences between estimates from models 1a and 1b can be easily understood. The idea behind model 
1a is that survival is given by the mortality among cancer patients minus a ’normal’ mortality that may vary 
with sociodemographic characteristics. In model 1b, however, it is a constant ’normal’ mortality that is 
subtracted. For example, the true excess mortality (µc*) at educational level E* is lower than found when 
using a constant ’normal’ mortality (µc-*), and that at a higher educational level E** is higher (Figure 1). 
Stated differently, the higher mortality observed for cancer patients with education E* according to model 
1b is partly due to the fact that they would have had a higher mortality than those with E** also in the 
absence of the disease.                
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As expected, the bias is especially large when groups with widely different ’normal’ mortality are 
studied. For example, the excess mortality of divorced men (compared to that of the married) is particularly 
high according to model 1b.  
Although the differentials in the ‘normal’ mortality are substantial on a relative scale (up to 79 %), 
failure to correct for them does not matter much when this ‘normal’ mortality is generally low compared 
with cancer patients’ mortality. This is the reason why estimates from model 1a and 1b are so similar for 
lung cancer, pancreas cancer and stomach cancer, whereas they are more different for prostate cancer, 
bladder cancer and malignant melanoma. 
For the same reasons, differences were also found to be extra large when only the localized cancers 
were considered (not shown). For example, when all localized cancers in men were pooled together, the 
point estimates for marital status effects differed by as much as 0.07-0.15 between models 1a and 1b. For 
localized breast cancer in women, the corresponding figures were 0.08-0.14, which is considerably larger 
than the differences of 0.03-0.05 estimated in models for all breast cancers. Conversely, when a model was 
estimated only for prostate cancer with distant metastases, differences of 0.04-0.09 were found, whereas 
they were 0.09-0.22 for all prostate cancers.  
If follow-up had been increased to, say, 10 years, mortality among cancer patients would have been 
more dominated by ’normal’ mortality, and one would expect social gradients in survival according to 
model 1b to differ even more from  those obtained with model 1a.  This has not been checked here, but the 
Finnish study [9] suggests such a pattern.  
 
Comparison with models 2a and 2b 
 
Elimination of the first term (which corresponds to subtracting 0)  gives many estimates closer to 1, and               
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thus also closer to those from model 1a. This can be intuitively understood by taking a new look at Figure 
1. Given age, sex and period, the excess mortality at educational level E* according to model 1b is µc-* and 
that at educational level E** is µc-**. When no correction at all is made for ‘normal’ mortality, the ratio 
between the two levels would be (µc-*+µn-_)/(µc-**+µn_), which is larger than µc-*/µc-** if the latter is < 1 
and smaller if it is > 1. However, in a sample consisting of several ages and periods (as in this sex-specific 
analysis), estimates will not always be closer to 1. An estimate more different from one is seen, for 
example, for cervical cancer for better-educated women. (One particularly large difference is found for the 
few divorced women with malignant melanoma.) 
Social and marital differentials in non-cancer deaths are usually found to be sharper than those in 
cancer deaths.[16,17] This is consistent with the fact that exclusion of non-cancer deaths yields less 
pronounced effects of education and marital status (according to a comparison of results from model 2b 
with those from 2a).  
As Auvinen et al. [18] rightly pointed out, the excess mortality caused by a malignancy is higher than 
the registered cancer mortality among cancer patients and lower than their all-cause mortality. For that 
reason, they showed estimates from both kind of models in their study of social inequalities in cancer 
survival. However, it cannot be concluded that the social or marital differentials in the true excess mortality 
lie between those in registered cancer mortality and those in all-cause mortality. 
On the contrary, this study has demonstrated that both the results from model 2a and those from 2b 
tend to be overestimates of the differentials in the true aggressiveness of the disease (considered to be 
captured by model 1a). However, the differences are not very large, which should be a great comfort to 
researchers without access to data on sociodemographic variations in general mortality. For many 
important cancer sites, the differentials in prognosis between those who are married and those who are not, 
and between the poorly educated and the better-educated, can be analysed from a patient material               
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exclusively, above all if data allow non-cancer deaths to be excluded. The differences between models 2b 
and 1a for all cancers pooled were only 0.00-0.02. For some cancer sites, however, the choice of method is 
more important, although it can hardly be said to be critical. For example, while never-married men were 
found to have an excess mortality from prostate cancer that was 14 % higher than that of the married, 
according to the most complex model (1a), the corresponding parameter was 20 % in the cancer-mortality 
model estimated for cancer patients (2b) (and it was 24 % when only an age- and period specific ‘normal’ 
mortality was used in the relative-survival approach in model 1b). Similarly, a model for registered prostate 
cancer mortality gave an almost significant excess mortality of 6 percent for the widowed, while the 
estimate from the most complex model was 0. (The other models gave significant effects of 6 % or 7 %).  
 
 
The bottom line 
 
When the intention is to assess, for example, social or marital variations in survival within a relative-
survival approach, corresponding variations in ’normal’ mortality should be taken into account if possible. 
(Such variations are, of course, of no concern when the focus is on other determinants of cancer survival). 
In accordance with results reported from Finland, effects can be markedly different when ’normal’ 
mortality is assumed to depend only on age, sex, and period. The most extreme example is the doubling of  
the marital status differentials in survival from prostate cancer. Differences are smaller for the most 
aggressive cancers that strongly dominate mortality. Because the use of the simplest relative survival 
model exaggerates the steepness of the survival gradients for the less aggressive cancers in particular, and 
because these cancers are also tend to respond better to treatment than others, results from this model may 
be taken as more supportive of the treatment explanation (as opposed to the host-factor explanation; see               
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arguments in introduction) than they should be.  
Model 1a allows controls for sociodemographic variations (beyond those related to age, sex and 
period) in the population  without the cancer diagnosis under investigation. It is also practically convenient, 
but requires individual data including both persons with and persons without cancer (although not 
necessarily the whole national population). Also the Hakulinen-Tenkanen version can, of course, be used 
when the data required for model 1a is available. This approach allows similar controls for 
sociodemographic variations in ’normal’ mortality, but is in some respects less satisfying. One should 
expect the results to be very similar, but an empirical check of that is left to future studies. On the other 
hand, the Hakulinen-Tenkanen version has the advantage that it can be used also when only aggregate data 
are available for the ’normal’ population.  
  The results also confirm the conclusion from the Finnish study that, when data do not allow a 
sufficiently broad range of sociodemographic variations in ’normal’ mortality to be taken into account, the 
best alternative is to model registered cancer mortality among cancer patients (model 2b). This model gives 
results that are somewhat different from those from model 1a, but the differences can hardly be said to be 
large. If data on cause of death are not available either, one may well choose the simplest model (2a). This 
model was not estimated in the Finnish study, but it is found here that it performs better than the 
technically more cumbersome relative-survival approach (1b), using the most complex model as the 
yardstick. Fortunately, both these less data demanding models compare well with the most complex model 







Thanks are due to Statistics Norway for allowing the use of the data. Comments from Dr Steinar Tretli 
and two anonymous referees are greatly appreciated.  
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Table 1.  Estimates (with 95% confidence intervals) of differentials in ‘normal’ mortality 
and excess mortality from colorectal cancer among Norwegian men, according to register and 
census data for 1960-1991 
____________________________________________________________________________ 







CONSTANT          0.0025 deaths per person per month   
 
EDUCATIONAL LEVEL    
7 -9 years
a   282421    1  
10-12         80673    0.86*  (0.85-0.86) 
13-16        17114    0.75*  (0.74-0.77) 
17-          6521    0.64*  (0.62-0.66) 
 
AGE  50-54        22402    0.24*  (0.23-0.24) 
55-59        35849    0.39*  (0.38-0.39) 
60-64        54194    0.63*  (0.62-0.63) 
65-69
a        75718    1 
70-74        94996    1.60*  (1.59-1.62) 




a  111569   1 
1970-79    130520   1.03*  (1.02-1.03) 
1980-85        66898    0.99*  (0.98-1.00) 









EDUCATIONAL LEVEL    
7 -9 years
a   7089    1 
10-12      2555   0.95*  (0.90-1.00) 
13-16        665    0.87*  (0.80-0.96) 
17-        292    0.83*  (0.73-0.95) 
 
AGE  50-54        539    0.95  (0.86-1.05) 
55-59        921    0.93  (0.86-1.01) 
60-64    1496   0.96  (0.89-1.03) 
65-69
a    2194   1 
70-74    2660   1.09*  (1.02-1.16) 




a  2284   1 
1970-79    3376   0.80*  (0.75-0.85) 
1980-85    2161   0.65*  (0.61-0.70) 




a 1789    1 
transverse, descendence  1412    1.09*  (1.01-1.18) 
sigmoideum   2839    1.03  (0.96-1.10) 
rectum    4561   1.27*  (1.19-1.35) 









a    2630   1 
regional    3735   2.42*  (2.26-2.59) 
distant    4080   12.61*  (11.82-13.44) 







a    379    1 
adenocarc.,   moderately 
  differentiated    1911    1.20*  (1.05-1.39) 
(adeno)carc.,  poorly diff.   830    2.37*  (2.04-2.75) 




a   Arbitrarily chosen reference category 
b   This excess mortality, which is experienced for men  in the reference categories, corresponds to a 5-year relative survival of 74% 
 
*   significant at the 0.05 level 
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Table 2. Estimates (with 95% confidence intervals) of educational differentials in excess mortality from 
cancer among Norwegian men and women, by cancer site, according to register 
and census data for 1960-1991
a   
__________________________________________________________________________________________________________ 
 
WOMEN     MEN 
________________   __________________ 
Number     Number 
of  deaths     of  deaths 
 






b      7-  9      5361  1        8809  1 
10-12    1079  1.00  (0.93-1.07)   2113  0.95*  (0.90-0.99) 
13-16        135  0.96  (0.80-1.14)      408  0.94  (0.84-1.04) 




c   7-  9      6923  1        7089  1 
10-12    1871  0.87*  (0.82-0.92)   2555  0.95*  (0.90-1.00) 
13-16        352  0.89  (0.80-1.01)        665  0.87*  (0.80-0.96) 
17-                           292  0.83*  (0.73-0.95) 
 
PANCREAS
d     7-  9      2597  1        3105  1 
10-12        707  1.04  (0.95-1.13)    1029  0.93*  (0.87-1.00) 
13-16        119  0.79*  (0.65-0.95)      256  0.80*  (0.71-0.92) 




e      7-    9    2798  1     11252  1   
10-12        961  1.04  (0.96-1.12)      3635  0.93*  (0.89-0.97) 
13-16        185  1.15  (0.99-1.34)        705  0.87*  (0.81-0.94) 
17-                 254  0.82*  (0.72-0.93) 
 
BREAST
f     7-  9      8170  1 
10-12     2721  0.91* (0.86-0.96) 
13-        548  0.76*  (0.69-0.84)   
 
CERVIX
g     7- 9      2650  1 
10-12        624  1.05  (0.95-1.16) 
13-          89  0.91  (0.72-1.14) 
 
CORPUS UTERI
h   7-  9      1766  1 
10-12        507  0.96  (0.95-1.08) 
13-          95  0.89  (0.69-1.13) 
 
OVARIES
i     7-   9      4540  1 
10-12     1538  1.00  (0.93-1.06) 
13-        298  0.91  (0.81-1.03) 
 
PROSTATE
j     7-    9         9310  1 
10-12         3054  0.90*  (0.85-0.95) 
13-16             693  0.96  (0.87-1.06) 
17-             314  0.66*  (0.56-0.76) 
 
BLADDER
k     7-  9    1176  1     3018  1 
10-12        252  0.83*  (0.71-0.97)    1094  0.89*  (0.81-0.97) 
13-16          47  0.70*  (0.50-0.98)      215  0.79*  (0.66-0.94) 
17-                 91  0.59*  (0.44-0.80) 
_______________________________________________________________________________________________________ 









    7-  9        606  1          895  1 
MELANOMA
l    10-12        298  1.01  (0.85-1.20)      487  0.72*  (0.63-0.83) 
13-16          71  0.77  (0.56-1.05)      153  0.58*  (0.47-0.72) 
17-                 63  0.60*  (0.44-0.83) 
 
LEUKEMIA
m     7-  9      2518  1        3091  1 
10-12        773  0.94  (0.86-1.02)    1093  0.90*  (0.83-0.97) 
13-16        121  0.84  (0.69-1.02)      261  0.81*  (0.71-0.93) 
17-             117  0.72*  (0.59-0.88) 
__________________________________________________________________________________________________________ 
 
ALL SITES     7- 9       38395  1        46323  1 
ABOVE
n       10-12       11198  0.96*  (0.94-0.98)    14953  0.92*  (0.90-0.93) 
13-16         2037  0.86*  (0.82-0.91)      3757  0.88*  (0.84-0.91) 
17-             1316  0.78*  (0.73-0.83) 
__________________________________________________________________________________________________________ 
 
a   The models also included age, period, sub-site, stage, and  histological type/grade (the latter three only in the excess mortality term). 
b  The sub-site control variable had 4 categories:  i) pars pylorica, canalis, angulus, antrum, corpus , ii) previously recessed due 
 to benignant ulcer,  iii) several locations, and not specified, iv) all other. The histologic control  variable had 4 categories: 
 i) well differentiated adenocarcinoma, ii) moderately well differentiated adenocarcinoma,  iii) poorly differentiated 
adenocarcinoma or carcinoma, iv) all other 
c  The sub-site control variable had 4 categories:  i) caecum and colon ascendence,  ii) colon transversum and colon descendence, 
 iii) sigmoideum, iv) rectum. The few other colon subsites and the anal channel were excluded. The histologic control  variable had 4 
 categories:  i) well differentiated adenocarcinoma, ii) moderately well differentiated adenocarcinoma,  iii) poorly differentiated 
adenocarcinoma or carcinoma, iv) all other 
d  The sub-site control variable had 3 categories:  i) caput (head),  ii) pancreas not specified, iii) all other. The histologic control  variable had 4 
 categories:  i) well differentiated adenocarcinoma, ii) moderately well differentiated adenocarcinoma,  iii) poorly differentiated 
adenocarcinoma or carcinoma, iv) all other 
e   Two histologic control  variables were included. One of them was grade:  i) well differentiated,  ii) moderately well differentiated,  iii) poorly 
 differentiated, iv) all other. The other was type:  i) squamous cell carcinoma, ii) small-cell  carcinoma, iii) adenocarcinoma, 
 iv) all other. 
f  The histologic control  variable had 4 categories, referring only to grade: i) well differentiated, ii) moderately well differentiated, 
 iii) poorly differentiated, iv) all other 
g   Two histologic control  variables were included. One of them was grade:  i) well differentiated,  ii) moderately well differentiated,  iii) poorly 
 differentiated, iv) all other. The other was type i) adenocarcinoma, ii) squamous cell carcinoma, iii) all other 
h   Two histologic control  variables were included. One of them was grade:  i) well differentiated,  ii) moderately well differentiated,  iii) poorly 
 differentiated, iv) all other. The other was type i) adenocarcinoma, ii)  adenosquamous carcinoma, adenocanthoma, iii)  leiomyoma,  
iv) all other 
i   Two histologic control  variables were included. One of them was grade:  i) well differentiated,  ii) moderately well differentiated,  iii) poorly 
 differentiated, iv) all other. The other was  type i) adenocarcinoma,ii) serous cystadenocarcinoma, ii) mucinoust cystadenoma, iv) all other 
j  The histologic control  variable had 4 categories:  i) well differentiated adenocarcinoma or carcinoma, ii) moderately well 
 differentiated adenocarcinoma or carcinoma,  iii) poorly differentiated adenocarcinoma or carcinoma, iv) all other 
k   The few cancers in urethra were excluded. The histologic control variable had 4 categories: i) slightly atypical transitional and papillary tumor   
 or (in older classification)  well  differentiated adenocarcinoma or squamous cell carcinoma, ii) somewhat atypical transitional or papillary 
 tumor  or (in older classification)   moderately well  differentiated adenocarcinoma or squamous cell carcinoma,  iii) markedly atypical 
 transitional or  papillary tumor or (in older classification)  poorly  differentiated adenocarcinoma or squamous cell carcinoma, iv) all other  
l   The sub-site control variable had 4 categories:  i) head and neck,  ii) body excl. breast,  iii)  upper-extremeties/lower extremeties except feet,  
iii) all other. The histologic control  variable had 4 categories:  i) malignant melanoma with superficial spread, invasive, ii) nodular malignant 
 melanoma, iii) lentigo malignant melanoma, iv) all other 
m  The histology/sub-site variable had 7 categories: i) myelomatosis, ii) chronic lymphoctyic leukemia, iii) chronic myelocytic leukemia, iv) acute 
 leukemia/blast leukemia , v) acute lymphocytic leukemia, vi) acute myelocytic leukemia, vii) all other leukemia. Stage was not a relevant 
 variable. 
n     This particular model also included age, period, stage and site (the latter two, when relevant, only in the excess mortality term). 
  
*   significant at the 0.05 level               
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Table 3. Estimates of educational differentials in excess mortality from cancer among Norwegian men 
and women, by cancer site, according to different methods, 1960-1991
a   
___________________________________________________________________________________________________________ 
 
Models for women      Models for men 




STOMACH  10-12    1.00 0.99 0.99 1.00     0.95*  0.94*  0.94*  0.94* 
13-16    0.96 0.95 0.94 0.95     0.94 0.92 0.92*  0.91 
17-         0.85  0.83*  0.84*  0.84 
 
COLON/  10-12   0.87* 0.86* 0.86* 0.87*     0.95* 0.93* 0.94* 0.93* 
RECTUM  13-16    0.89 0.87*  0.87*      0.90     0.87*  0.84*  0.85* 0.86* 
17-                     0.83*  0.78* 0.80* 0.83* 
 
PANCREAS 10-12    1.04 1.03 1.03 1.03     0.93*  0.93*  0.93*  0.95 
13-16   0.79* 0.78* 0.79* 0.76*     0.80* 0.80* 0.80* 0.79* 
17-         1.04  1.03  1.03  1.04 
 
LUNG    10-12    1.04 1.03 1.03 1.03     0.93*  0.92*  0.93*  0.93* 
13-16    1.15 1.14 1.14 1.13     0.87*  0.86*  0.87*  0.86* 
17-         0.82*  0.80*  0.81*  0.80* 
 
BREAST 10-12    0.91*  0.88*  0.89* 0.90* 
13-   0.76*  0.73* 0.75* 0.76* 
 
CERVIX 10-12   1.05  1.03  1.02 1.05 
13-   0.91  0.89  0.87 0.96 
 
CORPUS 10-12    0.96  0.93 0.92 0.98 
UTERI   13-   0.89  0.84 0.84 0.92 
 
OVARIES  10-12    1.00 0.99 0.99 0.99 
13-    0.91 0.90 0.90 0.89 
 
PROSTATE  10-12         0.90*  0.86*  0.89* 0.91* 
13-16         0.96  0.89*  0.90*  0.94* 
17-         0.66*  0.56* 0.65* 0.70* 
 
BLADDER  10-12   0.83* 0.81* 0.83* 0.81*     0.89* 0.85*  0.88* 0.87* 
13-16   0.70* 0.66* 0.72* 0.69*     0.79* 0.74*  0.76* 0.79* 
17-         0.59*  0.49*  0.62* 0.64* 
 
MALIGNANT 10-12   1.01  0.97  0.95  0.94       0.72*  0.70*  0.75* 0.72* 
MELANOMA 13-16   0.77  0.71* 0.78* 0.69       0.58*  0.55*  0.62*  0.62* 
17-         0.60*  0.55*  0.59*  0.63* 
 
LEUKEMIA 10-12    0.94 0.93 0.93 0.92     0.90*  0.89*  0.90*  0.89* 
13-16    0.84 0.84 0.84 0.84     0.81*  0.80*  0.81*  0.82* 
17-         0.72*  0.71*  0.71* 0.71* 
__________________________________________________________________________________________________________ 
 
ALL  SITES    10-12   0.96* 0.94* 0.94* 0.95*     0.92* 0.90* 0.91* 0.91* 
ABOVE    13-16   0.86* 0.84* 0.85* 0.86*     0.88* 0.85*  0.86* 0.87* 




a   The models also included age, period, sub-site, stage, and  histological type/grade (the latter three, when relevant, only in the excess mortality 
term). 
The sub-site and histologic control variables were as defined in Table 2. Only effects relative to those with 7-9 years of education are shown.   
Differences of  0.03-0.05, when compared with results from model 1a, are in bold types, and those larger than 0.05 are in bold, underlined types. 
 




Table 4. Estimates (with 95% confidence intervals) of marital differentials in excess 





WOMEN     MEN 
________________   __________________ 
Number     Number 
of  deaths     of  deaths 
 





STOMACH  never-married         991    1.09*  (1.02-1.18)    1285    1.14*  (1.07-1.21)   
married
a          3734   1     8964   1 
       divorced/separated       226    0.98   (0.85-1.13)      336    1.15*  (1.02-1.29) 




never-married         1341   1.17*  (1.09-1.25)     1130   1.27*  (1.18-1.36)    
married
a          5434   1       8391   1      
       divorced/separated       356    0.96  (0.85-1.08)       343    1.00   (0.87-1.14)     
widowed       2015     1.01  (0.95-1.07)       737    1.06   (0.96-1.16)     
 
PANCREAS
   never-married         401    1.16*  (1.04.1.30)       475    1.05  (0.95-1.15) 
married
a          2033    1         3516    1 
       divorced/separated       162    1.18*  (1.00-1.39)       192    1.33*  (1.14-1.54) 
widowed         825    0.95  (0.87-1.04)       292    1.08  (0.95-1.23) 
 
LUNG    never-married         402    1.14*  (1.02-1.27)      1473    1.24*  (1.17-1.31) 
married
a          2373    1        12562    1 
       divorced/separated       361    1.17*  (1.05-1.31)        920    1.18*  (1.10-1.26) 
widowed         808    1.19*  (1.09-1.30)        927    1.13*  (1.05-1.21) 
 
BREAST  never-married       1907    1.11*  (1.05-1.18) 
married
a          7161    1 
       divorced/separated       443    1.06  (0.94-1.18) 
widowed       1928    1.06  (0.99-1.13) 
 
CERVIX  never-married         341    1.27*  (1.12-1.44) 
married
a          2093    1 
       divorced/separated       369    1.26*  (1.12-1.43) 
widowed         560    1.04  (0.92-1.16) 
 
CORPUS UTERI 
never-married         444    1.04  (0.92-1.19)   
married
a         1387    1 
       divorced/separated         74    0.90  (0.68-1.21) 
widowed         463    0.99  (0.86-1.13) 
 
OVARIES  never-married         983    1.09*  (1.01-1.18) 
married
a         4178    1 
       divorced/separated       253    1.03  (0.90-1.18) 
widowed         962    1.01  (0.93-1.09) 
 
PROSTATE  never-married             1317   1.14*  (1.06-1.24) 
married
a          1 0 4 6 4    1  
       divorced/separated                  430    1.23*  (1.07-1.41) 
widowed            1151   1.00  (0.91-1.10) 
 
_____________________________________________________________________________________________________________ 






   never-married         237    0.89  (0.75-1.05)        489    1.53*  (1.36-1.72)     
married
a            789    1          3449    1 
       divorced/separated         88    1.09  (0.85-1.41)        153    1.18  (0.94-1.48)   




  never-married         127    0.97  (0.76-1.24)        178    1.65*  (1.37-1.98) 
married
a             667    1          1312    1 
       divorced/separated         40    0.74  (0.47-1.16)          54    1.09  (0.77-1.53) 
widowed         141    0.79  (0.60-1.03)          54    1.22  (0.83-1.80) 
 
LEUKEMIA  never-married         452    1.05  (0.94-1.18)        454    1.11  (0.99-1.27)     
married
a          2144    1          3698    1 
       divorced/separated       100    0.90  (0.72-1.12)        114    1.07  (0.86-1.32) 





ABOVE   never-married       7501    1.14*  (1.11-1.17)      6927    1.20*  (1.17-1.24) 
married
a      31693   1     51946   1 
       divorced/separated     2422    1.07*  (1.03-1.12)      2592    1.19*  (1.14-1.24) 




a   The models also included age, period,  sub-site, stage, and  histological type/grade (the latter three, when relevant, only in the excess 
 mortality term).  The sub-site and histologic control variables were as defined in Table 2.  
 
*   significant at the  0.05 level 
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Table 5. Estimates of marital differentials in excess mortality from cancer among Norwegian men and 
women, by cancer site, according to different methods, 1960-1991
a 
___________________________________________________________________________________________________________ 
Models for women      Models for men 
1a 1b 2a 2b     1a 1b 2a 2b 
___________________________________________________________________________________________________________ 
 
STOMACH  never-married       1.09*  1.10*  1.10*  1.10*      1.14*  1.16*  1.15*  1.15* 
       divorced/separated     0.98   0.99  0.99  0.96      1.15*  1.19* 1.18* 1.14* 
widowed       1.01   1.02  1.02  1.02      1.10*  1.11*  1.11*  1.12* 
 
COLON/  never-married       1.17*  1.19*  1.18*  1.18*      1.27*  1.31* 1.28* 1.31* 
RECTUM    divorced/separated     0.96  0.99 0.98 0.95            1.00    1.10 1.10  1.11 
widowed       1.01  1.02  1.03  1.01        1.06   1.11*  1.08*  1.10* 
 
PANCREAS
   never-married       1.16*  1.16*  1.16*  1.15*         1.05  1.05  1.05  1.05 
       divorced/separated     1.18*  1.17*  1.17*  1.17      1.33*  1.34*  1.34*  1.26* 
widowed       0.95  0.95  0.95  0.95      1.08  1.09  1.09  1.11 
 
LUNG   never-married         1.14*  1.14*  1.14*  1.14*    1.24*  1.25*  1.25*  1.25* 
       divorced/separated     1.17*  1.18*  1.18*  1.13*    1.18*  1.20*  1.20*  1.19* 
widowed       1.19*  1.19*  1.19*  1.18*      1.13*  1.14*  1.13*  1.12* 
 
BREAST  never-married       1.11*  1.15* 1.12* 1.15* 
       divorced/separated     1.06  1.11* 1.11* 1.05 
widowed       1.06  1.09*  1.07*  1.10* 
 
CERVIX  never-married       1.27*  1.29*  1.26*  1.29* 
       divorced/separated     1.26*  1.30*  1.28* 1.26* 
widowed       1.04  1.05  1.05  1.05 
 
CORPUS  never-married       1.04  1.07  1.06  1.05 
UTERI    divorced/separated     0.90  0.95 0.95 0.95 
widowed       0.99  1.02 1.04 1.01 
 
OVARIES  never-married       1.09*  1.10*  1.10*  1.10* 
       divorced/separated     1.03  1.05  1.05  1.04 
widowed       1.01  1.01  1.02  1.00 
 
PROSTATE  never-married         1.14*  1.24* 1.19*  1.20* 
         divorced/separated        1.23*  1.45* 1.34*  1.20 
widowed        1.00  1.09* 1.07*  1.06 
 
BLADDER
   never-married       0.89  0.91  0.93*  0.91          1.53*  1.62* 1.47* 1.51* 
       divorced/separated     1.09 1.13  1.15  1.03    1.18  1.38* 1.29*  1.20* 
widowed       1.04  1.06  1.06  1.05      1.31*  1.40* 1.25* 1.35* 
 
MALIGNANT
  never-married       0.97  1.01  1.00  1.04    1.65*  1.71* 1.56*  1.69* 
MELANOMA  divorced/separated     0.74  0.81  1.01   0.69    1.09  1.21  1.20  1.17 
widowed       0.79  0.82  0.87       0.95    1.22  1.32  1.16  1.18 
 
LEUKEMIA  never-married       1.05  1.06  1.05  1.09         1.11  1.14* 1.13* 1.12* 
       divorced/separated     0.90  0.94  0.93  0.91    1.07  1.16 1.12 1.06 
widowed       1.09  1.11*  1.09  1.11         1.07  1.09  1.09  1.10 
__________________________________________________________________________________________________________ 
 
ALL SITES  never-married       1.14*  1.16*  1.14*  1.16*        1.20*  1.24*  1.23* 1.22* 
ABOVE      divorced/separate      1.07*  1.10* 1.09* 1.06*     1.19* 1.26*  1.24*  1.20* 
widowed         1.06*  1.07*  1.06*  1.07*      1.09*  1.12* 1.11* 1.11* 
__________________________________________________________________________________________________________ 
 
a   The models also included age, period,  sub-site, stage, and  histological type/grade (the latter three, when relevant, only in the excess 
mortality term). Only effects relative to the married are shown.  The sub-site and histologic control varaibles were as defined in Table 2. 
Differences  
of  0.03-0.05, when compared with results from model 1a, are in bold types, and those larger than 0.05 are in bold, underlined types. 
 
*   significant at the  0.05 level               
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